Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Würselen – page 109

1 367 clinical trials in Würselen, Germany across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Würselen at a glance
1 367
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

1 367 trials in Würselen

Open in trial search

Study on the Effect of DA-EPOCH-R and Nivolumab in Patients with Newly Diagnosed High-Grade B-Cell Lymphoma with MYC and BCL2/BCL6 Rearrangements

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Fallopian tube cancer+1

Not recruiting

Study on Treatment for Recurrent Platinum-Sensitive Ovarian, Peritoneal, or Fallopian Tube Cancer Using Carboplatin and Mirvetuximab Soravtansine in Eligible Patients

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Breast cancer

Not recruiting

Study Comparing ARV-471 and Fulvestrant for Patients with Advanced Estrogen Receptor-Positive, HER2-Negative Breast Cancer After Endocrine Treatment

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Fulvestrant
  • Sponsor:Pfizer Inc.

Malignant melanoma

Not recruiting

Study on Nivolumab for Preventing Melanoma Recurrence in Patients with Completely Removed Stage IIB/C Melanoma

Registered drug
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Hidradenitis

Not recruiting

Study on the Effectiveness and Safety of Povorcitinib for Patients with Moderate to Severe Hidradenitis Suppurativa

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Povorcitinib
  • Sponsor:Incyte Corp.

Acute kidney injury

Not recruiting

Study on Ravulizumab for Protecting Chronic Kidney Disease Patients from Acute Kidney Injury After Heart Surgery

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ravulizumab
  • Sponsor:Alexion Pharmaceuticals Inc.

Polycythaemia vera

Not recruiting

Study on Hydroxycarbamide Resistance in Patients with Polycythemia Vera Identified by AI Predictors

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Hydroxycarbamide
  • Sponsor:Novartis Pharma GmbH

Study of Capivasertib with CDK4/6 Inhibitors and Fulvestrant for Patients with Advanced HR+/HER2- Breast Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:AstraZeneca AB

Hidradenitis

Not recruiting

Study to Evaluate the Effectiveness of Spesolimab for Patients with Moderate to Severe Hidradenitis Suppurativa

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Spesolimab
  • Sponsor:Boehringer Ingelheim Espana S.A.

Neoplasm malignant

Not recruiting

Continued Darolutamide Treatment for Cancer Patients from Previous Bayer Studies

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Darolutamide
  • Sponsor:Bayer Consumer Care AG

Cardiac amyloidosis

Not recruiting

Study on Long-Term Safety of Eplontersen for Adults with Transthyretin-Mediated Amyloid Cardiomyopathy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ascorbic Acid
  • Sponsor:Ionis Pharmaceuticals Inc.

COVID-19+2

Not recruiting

Study on Everolimus and Mycophenolate Mofetil for Improving COVID-19 Vaccine Response in Kidney Transplant Patients

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Everolimus
  • Sponsor:Universitair Medisch Centrum Groningen

Other cities in Germany

The busiest research cities in the country

All 503 cities in Germany

Clinical research in Würselen

What the registry says about research in the country

01 Urological Oncology

Innovative research focusing on non-muscle invasive bladder cancer, evaluating combination therapies including immunotherapy approaches. These trials aim to improve treatment outcomes and reduce recurrence rates.

  • BCG Combination Therapy
  • Novel Immunotherapy Approaches
  • Disease-Free Survival Studies

Examining alternative treatment options including natural compounds for bladder cancer management.

02 Hematologic Disorders

Advanced research into polycythemia vera treatment resistance, utilizing artificial intelligence to predict therapeutic outcomes. Studies focus on optimizing hydroxyurea treatment protocols.

  • AI-Driven Treatment Prediction
  • Drug Resistance Analysis
  • Personalized Medicine Approaches

Integration of machine learning technologies to enhance treatment effectiveness.

03 Prostate Cancer Research

Comparative studies evaluating different dosing regimens for metastatic prostate cancer treatments, focusing on optimizing therapeutic combinations while minimizing adverse effects.

  • Treatment Safety Profiles
  • Dosing Schedule Optimization
  • Combination Therapy Assessment

Investigating innovative approaches to enhance treatment tolerability and effectiveness.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.